Alkermes Highlights Innovations in Psychiatry at Spring Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
Alkermes plc (Nasdaq: ALKS) has recently announced its participation in significant scientific conferences this spring, where they presented groundbreaking research focusing on their psychiatric products, LYBALVI (olanzapine and samidorphan) and ARISTADA (aripiprazole lauroxil). These events, coinciding with Mental Health Awareness Month, provided a critical platform to advocate for those affected by mental health conditions and to highlight the efforts of healthcare professionals in this field.
Key Scientific Meetings Attended
Alkermes took this opportunity to showcase its research at several notable scientific gatherings, including:
- American Association of Psychiatric Pharmacists (AAPP) Annual Meeting
- The Neuroscience Education Institute (NEI) Spring Congress
- The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference
- American Psychiatric Association (APA) Annual Meeting
- American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
- Psych Congress Elevate
Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes, shared, "Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry. We remain committed to enhancing patient care and contributing to the growing evidence within neuro-psychiatry, particularly for schizophrenia and bipolar I disorder. These gatherings are invaluable for fostering connections with fellow stakeholders."
Research Highlights and Presentations
Among the numerous presentations made, several stood out, particularly:
- First-time presentation revealing insights on lipid and glycemic profiles for adult patients treated with LYBALVI over four years.
- An extensive review on the safety and tolerability of LYBALVI in various patient subgroups.
- A post hoc evaluation investigating the effects of LYBALVI on the negative symptoms of schizophrenia over a series of studies.
- Analyses related to ARISTADA’s efficacy and safety across differing initial severity levels among schizophrenia patients in a phase 3b study.
Alkermes provided detailed documentation of its presentations across the conferences classified by meeting:
American Association of Psychiatric Pharmacists (AAPP)
- Study Retention Rates in the Olanzapine/Samidorphan Phase 3 Clinical Program
- Healthcare Resource Utilization of Schizophrenia Patients
Neuroscience Education Institute (NEI)
- Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients with Schizophrenia
- Response to Treatment with Aripiprazole Lauroxil Every 2 Months
ISPOR Annual Conference
- Healthcare Resource Utilization Following Initiation of Olanzapine/Samidorphan
- Economic Burden of Narcolepsy: A National Survey Analysis
American Society of Clinical Psychopharmacology (ASCP)
- Long-Term Safety Assessment of Olanzapine and Samidorphan
- Impact of Treatment Patterns on Schizophrenia Outcomes
Psych Congress Elevate
- Assessment of Real-World Effectiveness of Olanzapine/Samidorphan
With a rich portfolio of proprietary products targeting mental health care, Alkermes is a frontrunner in developing treatments focused on alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, they are advancing an array of candidates aimed at neurological disorders such as narcolepsy. The company, with its headquarters in Ireland and facilities in Massachusetts and Ohio, continues to push the boundaries of neuroscience.
Frequently Asked Questions
What is the focus of Alkermes' presentations at the conferences?
Alkermes presented research primarily related to their psychiatry products, including LYBALVI and ARISTADA, focusing on safety and efficacy studies.
In what areas does Alkermes specialize?
Alkermes specializes in developing innovative treatments for mental health conditions, particularly schizophrenia and bipolar I disorder.
Who is the Chief Medical Officer of Alkermes?
Craig Hopkinson, M.D., is the Chief Medical Officer and Executive Vice President of Research & Development at Alkermes.
What are the primary products of Alkermes?
Some of Alkermes' primary products include LYBALVI (for schizophrenia and bipolar I disorder) and ARISTADA (for schizophrenia).
Where is Alkermes headquartered?
Alkermes is headquartered in Ireland, with additional facilities in Massachusetts and Ohio.
